DMD Therapeutics
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotech, Life Sciences
- Founded
- 2017
- Stage
- Seed
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about DMD Therapeutics
UW spinout DMD Therapeutics raises $400,000 from three foundations to advance DMD-813 toward human trials
DMD Therapeutics, a University of Washington spinout led by Ron Berenson, raised $400,000 from three DMD-focused foundations to advance its lead candidate DMD-813 — which showed positive results in mouse studies — toward human trials and early manufacturing.
Seattle Serial Entrepreneur Ron Berenson’s New UW Spin‑Off DMD Therapeutics Files to Raise $600,000
Ron Berenson has launched a new Seattle biotech startup, DMD Therapeutics, which filed to raise $600,000 with Berenson listed as president; the company is a University of Washington spin-off currently operating in stealth mode. Berenson is a serial entrepreneur who leads several other biotech and medical companies and has a long history in Seattle’s biotech scene.
Questions about DMD Therapeutics
What is DMD Therapeutics?
Seattle, WA, US
Who invested in DMD Therapeutics, and how much has it raised?
Members of Seattle Flow see DMD Therapeutics' funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is DMD Therapeutics based?
DMD Therapeutics is headquartered in Seattle, WA, US.
When was DMD Therapeutics founded?
DMD Therapeutics was founded in 2017.